SCA Pharma
Overview:
- Headquarters: Little Rock, Arkansas, USA
- Establishment: 2010
- Business Model: FDA-registered 503B outsourcing facility specializing in sterile compounded medications for hospitals and health systems nationwide.
Products:
- Ready-to-use sterile compounded medications
- IV admixtures
- Pre-filled syringes
Strengths:
- High-quality standards and compliance with FDA regulations
- Efficient production and delivery systems
- Strong customer relationships
Opportunities:
- Expansion into new healthcare markets
- Adoption of advanced compounding technologies
- Strategic partnerships with healthcare providers
Challenges:
- Navigating complex regulatory environments
- Managing supply chain disruptions
- Ensuring consistent product quality
Recent Developments:
-
Expansion of production facilities to increase capacity and meet growing demand
Nephron Pharmaceuticals Corporation
Overview:
- Headquarters: West Columbia, South Carolina, USA
- Establishment: 2001
- Business Model: Contract manufacturing and 503B outsourcing facility focusing on respiratory medications and generic injectables.
Products:
- Respiratory medications (e.g., nebulized solutions)
- Generic injectable drugs
- Contract manufacturing services
Strengths:
- Advanced manufacturing capabilities
- Strong presence in the respiratory medication market
- Commitment to affordability and accessibility
Opportunities:
- Growth in the global respiratory care market
- Expansion of product portfolio
- Collaboration with healthcare providers and institutions
Challenges:
- Intense competition in the generic drug market
- Regulatory hurdles in international markets
- Maintaining cost-effectiveness while ensuring quality
Recent Developments:
-
Expansion of manufacturing facilities to enhance production capacity
Athenex, Inc.
Overview:
- Headquarters: Buffalo, New York, USA
- Establishment: 2003
- Business Model: Biopharmaceutical company focused on developing and commercializing novel therapies for cancer treatment.
Products:
- Oncology therapeutics
- Specialty pharmaceutical products
- 503B compounded medications
Strengths:
- Strong research and development pipeline
- Expertise in oncology treatments
- Diverse revenue streams through product sales and licensing agreements
Opportunities:
- Advancements in cancer treatment therapies
- Strategic partnerships and collaborations
- Expansion into emerging markets
Challenges:
- High costs associated with drug development
- Regulatory approval processes
- Market competition from established oncology brands
Recent Developments:
-
Restructuring efforts to streamline operations and focus on core competencies
Wells Pharma of Houston LLC
Overview:
- Headquarters: Houston, Texas, USA
- Establishment: Date not specified
- Business Model: FDA-registered 503B outsourcing facility providing compounded medications to hospitals and surgical centers.
Products:
- Sterile compounded medications
- IV admixtures
- Pre-filled syringes
Strengths:
- Quick turnaround times with most products shipping within 48 hours
- Experienced leadership with over 100 years of combined industry experience
- Dedicated and loyal staff
Opportunities:
- Expansion of product offerings
- Enhancement of distribution networks
- Collaboration with healthcare providers to meet specific needs
Challenges:
- Navigating legal disputes, such as the lawsuit filed by Zyla Life Sciences under unfair competition laws
- Managing operational costs
- Ensuring consistent product quality and compliance
Recent Developments:
-
Ongoing efforts to address legal challenges and maintain business operations
Olympia Pharmacy
Overview:
- Headquarters: Orlando, Florida, USA
- Establishment: 2009
- Business Model: FDA-registered 503B outsourcing facility and 503A compounding pharmacy specializing in a wide range of compounded medications.
Products:
- IV nutritional therapy
- Hormone replacement therapy
- Sexual health solutions
- Weight management medications
- Longevity treatments
Strengths:
- Broad product portfolio catering to diverse patient needs
- Licensed in 48 states, ensuring wide accessibility
- Expertise in personalized medicine
Opportunities:
- Growth in personalized and preventive healthcare
- Expansion into new therapeutic areas
- Strategic partnerships with healthcare providers
Challenges:
- Regulatory compliance across multiple states
- Maintaining product quality and consistency
- Competition from other compounding pharmacies
Recent Developments:
-
Continued expansion of product offerings to meet evolving patient needs
Fagron Compounding Pharmacies
Overview:
- Headquarters: Nazareth, Belgium / Rotterdam, Netherlands
- Establishment: 1990
- Business Model: Global leader in pharmaceutical compounding, providing products and services to healthcare professionals and institutions worldwide.
Products:
- Pharmaceutical compounding products
- Customized medications for hospitals and pharmacists
- Fagron-branded products
Strengths:
- Presence in over 29 countries
- Serving 150,000 customers in more than 55 countries
- Strong brand recognition in the compounding industry
Opportunities:
- Expansion into emerging markets
- Development of new compounding technologies
- Strategic acquisitions to enhance product offerings
Challenges:
- Regulatory challenges in international markets
- Managing a diverse product portfolio
- Ensuring consistent product quality across global operations
Recent Developments:
-
Reported a 6.4% revenue growth in the third quarter of 2025, reflecting strong performance in the compounding sector